{"id":"W4399369977","doi":"10.1016/s0140-6736(24)00701-3","title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Genentech; Astellas Pharma; Eisai; Servier; Moderna; Yuhan; LG Chem; Advanced Accelerator Applications; Sanofi; Halozyme; Exelixis; Ipsen; BeiGene; Mirati Therapeutics; Handok; Amgen; Pfizer; Recordati Rare Diseases; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Octreotide; Medicine; Neuroendocrine tumour; Neuroendocrine tumors; DOTA; Urology; Internal medicine; Nuclear medicine; Somatostatin; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005416048,0.0009295798,0.002130515,0.0002614154,0.000558585,0.0005205351,0.001509556,0.00001342399,0.000155457],"category_scores_gemma":[0.0009648257,0.0005554081,0.0002986601,0.0006384648,0.0003265517,0.0007138807,0.0003565909,0.0007427245,0.00003244907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003983591,"about_ca_system_score_gemma":0.0001963181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008919276,"about_ca_topic_score_gemma":0.001051929,"domain_scores_codex":[0.993979,0.0008227949,0.00119338,0.001285472,0.0009093452,0.001810037],"domain_scores_gemma":[0.9914322,0.005401323,0.0005334624,0.002007801,0.0001748748,0.0004503188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6760316,0.03100978,0.02401781,0.00311987,0.008080703,0.0880162,0.003993939,0.007330264,0.0253161,0.0001677223,0.00690949,0.1260065],"study_design_scores_gemma":[0.8520564,0.06866155,0.007892733,0.001421601,0.005393874,0.002807353,0.006595785,0.01887307,0.03144097,0.0002255019,0.003432481,0.001198666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799625,0.001814518,0.0003861123,0.005156443,0.001284225,0.01070091,0.0002304368,0.0003604494,0.0001044485],"genre_scores_gemma":[0.9924788,0.002143769,0.0006345526,0.0003050563,0.00100469,0.002054372,0.0001790815,0.0002487859,0.000950861],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1760248,"threshold_uncertainty_score":0.9996898,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08115582454593431,"score_gpt":0.3982719218759983,"score_spread":0.317116097330064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}